Pegcetacoplan (APL-2) in Neovascular AMD

Clinical trial NCT03465709 · TERMINATED

Trial details

NCT number: NCT03465709
Sponsor: Apellis Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neovascular Age-related Macular Degeneration

Start date: 2018-02-14
Primary completion: 2019-04-05
Enrollment: 17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.